Screener
Immunome IMNM Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 46,381 | 36,872 |
| General and administrative | 12,950 | 10,690 |
| Total operating expenses | 59,331 | 47,562 |
| Loss from operations | (59,331) | (44,636) |
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
| Net loss per share, basic and diluted | $(0.48) | $(0.52) |
| Weighted-average shares outstanding, basic and diluted | 113,136,836 | 79,410,354 |
Item 1. Financial Statements.
FAQ
- What is Immunome's operating income?
- Immunome (IMNM) reported operating income of -$59.33M in Q1 2026.
- How has Immunome's operating income changed year-over-year?
- Immunome's operating income decreased by 32.9% year-over-year, from -$44.64M to -$59.33M.
- What is the long-term trend for Immunome's operating income?
- Over 4 years (2021 to 2025), Immunome's operating income has grown at a 72.7% compound annual growth rate (CAGR), from -$25.2M to -$224.11M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Immunome's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude